A pharmaceutical company based in Korea is actively searching for innovative candidates and products around the world to incorporate into its pipeline and product portfolio. The firm has ample experience across various types of partnerships with overseas companies and is flexible in terms of the business structure. The firm is interested globally, including world-wide major territories.
The firm is currently seeking promising novel therapeutic candidates to incorporate into its pipeline. In terms of indications, the firm is indication agnostic with added interest in CNS, infection, oncology, and immunology. The firm is also interested in other therapeutic areas that address unmet medical needs, including orphan diseases. The firm prefers assets from IND ready to late stage development. The firm is also interested in obtaining distribution rights for innovative treatment in Phase III or in marketing authorization process.
The firm is open to working with companies anywhere in the world, and has no set requirements for partners; The firm is able to work with virtual drug companies by leveraging the firm’s own capabilities and third party relationships.